Polyphor Ag

Unversität Zürich

Universitaet Zuerich

Virometix Ag

Universität Zürich, Prorektorat Forschung

Kerstin Möhle

Daniel Obrecht

Frank Gombert

Christian Ludin

John Anthony Robinson

Barbara Romagnoli

Alexander Lederer

Anatol Luther

Jan Wim Vrijbloed

Reshmi Mukherjee

Philipp Ermert

Christian Bisang

Sergio Lociuro

Odile Sellier-Kessler

Said Oumouch

Arin Ghasparian

Franck Lach

Karsten Marx

Aniebrys Marrero Nodarse

Armando Zuniga

Francesca Boato

Anabelle Freund

Richard M Thomas

Oliver Rassek

Reshimi Mukherjee

Steve J Demarco

Markus Seitz

Ludovic T Maillard

Roba Mounme

Annabelle Freund

John A Robinson

The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

Cyclic peptides for protection against respiratory syncytial virus

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT(5-HTreceptor), and on the prostaglandin F2&#x2022;receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour. 

Conformationally constrained, fully synthetic macrocyclic compounds

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y, as modulators of the serotonin receptor of subtype 5-HT, as blockers of the voltage-gated potassium channel K1.3 and as inhibitors of the &#x3b2;-catenin-dependent 'canonical' Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases. 

The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.

Coiled-coil lipopeptide helical bundles and synthetic virus-like particles

Growing community of inventors

Wettswil, Switzerland

Kerstin Möhle